Clinuvel hopes to shine as photoprotective nears market
22 May 2009
Simon Varcoe
simon.varcoe@informa.com
Clinuvel's only product, afamelanotide, will be ready to launch in Europe by the end of next year, and the company is still on track to become a billion-dollar firm, its CEO
Dr Philippe Wolgen told
Scrip.
The prophylactic photoprotective agent is expected to complete final Phase...
Please Login to read the full article.